ProQR raised about $59.2 million in June, through a $50.0 million underwritten registered direct offering and a $9.2 million private placement to Eli Lilly and Company. The release names no underwriter, and says cash of €117.1 million covers runway into mid-2028.
ProQR is registering 3,030,303 shares for resale by a holder the prospectus calls Ginkgo, issued in April 2026 under a share purchase agreement tied to a services contract. ProQR receives none of the proceeds, and the prospectus gives no per-share price for the shares.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about ProQR Therapeutics
Has ProQR Therapeutics raised money recently?
Our latest story on this, dated Aug 13, 2026: "ProQR reports $59.2 million June financing and €117.1 million cash". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of ProQR Therapeutics?
ProQR Therapeutics N.V. trades under the ticker PRQR on NASDAQ.
Where is ProQR Therapeutics listed?
ProQR Therapeutics N.V. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0PQ; LS:A12B97; LSX:A12B97.
What is the SEC CIK of ProQR Therapeutics?
The SEC Central Index Key (CIK) for ProQR Therapeutics N.V. is 1612940. Its filings are on SEC EDGAR.
How many shares does ProQR Therapeutics have outstanding?
105,361,064 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-12.
Which country or territory is ProQR Therapeutics listed under?
Our directory records ProQR Therapeutics N.V. under Netherlands.
What does ProQR Therapeutics do?
Our directory classifies ProQR Therapeutics N.V. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of ProQR Therapeutics?
The ISIN recorded for ProQR Therapeutics N.V. is NL0010872495.
Does aibio.space cover ProQR Therapeutics?
aibio.space lists ProQR Therapeutics N.V. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is ProQR Therapeutics incorporated?
SEC records list its state or country of incorporation as P7.
How much cash does ProQR Therapeutics have?
$74.8 million in cash at Sep 30, 2019, per its 6-K.
What is the latest ProQR Therapeutics (PRQR) stock news?
Our latest story on ProQR Therapeutics, dated Aug 13, 2026: "ProQR reports $59.2 million June financing and €117.1 million cash". ProQR raised about $59.2 million in June, through a $50.0 million underwritten registered direct offering and a $9.2 million private placement to Eli Lilly and Company. The release names no underwriter, and says cash of €117.1 million covers runway into mid-2028. Source.
Is ProQR Therapeutics a smaller reporting company?
SEC records list ProQR Therapeutics N.V.'s filer category as: Accelerated filer.
Where is ProQR Therapeutics headquartered?
SEC records list its business address as ZERNIKEDREEF 9, LEIDEN.
When does ProQR Therapeutics's fiscal year end?
ProQR Therapeutics N.V.'s fiscal year ends on December 31, per SEC records.
Investor discussion: ProQR Therapeutics
Members talk about ProQR Therapeutics (PRQR). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at ProQR Therapeutics, newest first. Each line links the filing it comes from.
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:PRQR on TradingView.
SEC filings and registration
SEC name
ProQR Therapeutics N.V.
CIK
1612940
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
PRQR (Nasdaq)
State or country of incorporation
P7
Fiscal year ends
December 31
Filer category
Accelerated filer
Business address
ZERNIKEDREEF 9, LEIDEN
Phone
31 88 166 7000
Shares outstanding
105,361,064 as of 2025-12-31 (20-F filed 2026-03-12)
Former names
ProQR Therapeutics B.V.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
ProQR Therapeutics N.V. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PRQR, recorded under Netherlands. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio